Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
REGULATORY
Nichi-Iko to Get Business Suspension Order on March 3
Toyama prefectural authorities and the Ministry of Health, Labor and Welfare (MHLW) are in the final stages of adjustments to issue a business suspension order to generic major Nichi-Iko Pharmaceutical on March 3 over a raft of voluntary recalls attributable…
To read the full story
Related Article
- Nichi-Iko Suspended from JGA Membership
March 10, 2021
- Nichi-Iko Chief Apologizes for GMP Violations, but Draws Clear Distinction from Kobayashi Kako Case
March 4, 2021
- Nichi-Iko Ordered to Suspend Biz over Sloppy Manufacturing
March 3, 2021
- Nichi-Iko Likely to Face Biz Suspension Order over Spate of Recalls
February 25, 2021
- Administrative Penalty on Nichi-Iko Possible by March-End over Recalls
January 15, 2021
- Nichi-Iko Announces Yet Another Recall, 38 Products Added to Bring Total to 75
January 14, 2021
- Nichi-Iko Stops Supply of Clinoril Due to Dissolution Issue
December 23, 2020
- Nichi-Iko Recalls 4 More Products Including Theophylline due to Deviations from Approved Specifications
December 11, 2020
- Some Hospitals Shun New Nichi-Iko Generics after Massive Recalls, President Reveals
November 13, 2020
- Nichi-Iko Recalls 7 More Products, Critical Eyes from Healthcare Professionals
November 11, 2020
- Nichi-Iko to Revamp Quality Control System after Massive Recalls by Leveraging Teva Takeda Plant
August 28, 2020
- Nichi-Iko Launches Another Recall, Now Pulling 8 More APIs/9 Products
May 19, 2020
- Nichi-Iko Recalling 12 APIs/15 Products over Quality, Compliance Issues
April 9, 2020
REGULATORY
- Japan Approves Zepbound, Qalsody, and Lots More Drugs
December 27, 2024
- Quality Assurance and Lag/Loss Fight to Form Pillars of PMD Act Amendment
December 27, 2024
- LDP Members Urge Ministers to End “Mechanical” Off-Year Price Cuts
December 27, 2024
- Japan to Set Up Fund to Spur Generic Shakeup; CEA, Market Expansion Re-Pricing on Agenda
December 26, 2024
- Gist of FY2025 Drug Price Revision
December 26, 2024
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…